

## United States Patent and Trademark Office



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/515,513	02/29/2000	Wu Bo Li	0942.4870001/RWE	1139
26111 75	06/10/2004		EXAMINER	
STERNE, KESSLER, GOLDSTEIN & FOX PLLC 1100 NEW YORK AVENUE, N.W.			SISSON, BRADLEY L	
	VASHINGTON, DC 20005		ART UNIT	PAPER NUMBER
			1634	
			DATE MAILED: 06/10/2004	

Please find below and/or attached an Office communication concerning this application or proceeding.

	,				
	Application No.	Applicant(s)			
Advisory Action	09/515,513	LI ET AL.			
	Examiner	Art Unit			
	Bradley L. Sisson	1634			
The MAILING DATE of this communication appe	ears on the cover sheet with the c	correspondence address			
THE REPLY FILED 21 May 2004 FAILS TO PLACE TH Therefore, further action by the applicant is required to a final rejection under 37 CFR 1.113 may only be either: (*condition for allowance; (2) a timely filed Notice of Appeter Examination (RCE) in compliance with 37 CFR 1.114.	void abandonment of this application (1) a timely filed amendment whi	cation. A proper reply to a ch places the application in			
PERIOD FOR RE	PLY [check either a) or b)]				
a) The period for reply expiresmonths from the mailing of the period for reply expires on: (1) the mailing date of this Adverse, will the statutory period for reply expire later the ONLY CHECK THIS BOX WHEN THE FIRST REPLY WAS 706.07(f).  Extensions of time may be obtained under 37 CFR 1.136(a). The dathave been filed is the date for purposes of determining the period of extensions CFR 1.17(a) is calculated from: (1) the expiration date of the shortened (b) above, if checked. Any reply received by the Office later than three mother patent term adjustment. See 37 CFR 1.704(b).	visory Action, or (2) the date set forth in the an SIX MONTHS from the mailing date of FILED WITHIN TWO MONTHS OF THe on which the petition under 37 CFR 1.7 sion and the corresponding amount of the statutory period for reply originally set in	f the final rejection. E FINAL REJECTION. See MPEP  136(a) and the appropriate extension fee efee. The appropriate extension fee under the final Office action; or (2) as set forth in			
1. A Notice of Appeal was filed on <u>21 May 2004</u> . App 37 CFR 1.192(a), or any extension thereof (37 CF					
2. The proposed amendment(s) will not be entered b	ecause:				
(a) X they raise new issues that would require furth	er consideration and/or search	(see NOTE below);			
(b) ☐ they raise the issue of new matter (see Note I					
(c) they are not deemed to place the application issues for appeal; and/or	•	terially reducing or simplifying the			
(d) they present additional claims without cance	ling a corresponding number of	finally rejected claims.			
NOTE: See Continuation Sheet.					
3. Applicant's reply has overcome the following reject	ction(s):				
4. Newly proposed or amended claim(s) would canceling the non-allowable claim(s).	l be allowable if submitted in a s	separate, timely filed amendment			
5. The a) affidavit, b) exhibit, or c) request for application in condition for allowance because:		sidered but does NOT place the			
6. The affidavit or exhibit will NOT be considered be raised by the Examiner in the final rejection.	cause it is not directed SOLELY	to issues which were newly			
7. For purposes of Appeal, the proposed amendmen explanation of how the new or amended claims w					
The status of the claim(s) is (or will be) as follows:					
Claim(s) allowed:					
Claim(s) objected to: <u>47-50,53-63 and 106</u> .					
Claim(s) rejected: <u>51,52 and 107</u> .					
Claim(s) withdrawn from consideration:					
☐ The drawing correction filed on is a)☐ approved or b)☐ disapproved by the Examiner.					
Note the attached Information Disclosure Statement(s)( PTO-1449) Paper No(s)					
10. Other:		B. F. Linicon			

Bradley L. Sisson Primary Examiner Art Unit: 1634

Continuation of 2. NOTE: The aspect of inhibiting a particular activity of the polypeptide, i.e., the reverse transcriptase activity, would raise a new issue that would require further consideration and/or search.